{"product_id":"ipca-marketing-mix","title":"Ipca Marketing Mix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGet Inspired by a Complete Brand Strategy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eDiscover how Ipca’s product portfolio, pricing architecture, distribution reach, and promotional tactics combine to create market impact—download the full 4P’s Marketing Mix Analysis in an editable, presentation-ready format to save hours of work and apply proven strategic insights.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eroduct\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Branded Formulations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIpca Laboratories holds leadership in rheumatology, pain management, and cardiovascular branded generics, with these segments contributing ~48% of domestic formulations revenue in FY2024-25 (reported FY end Mar 2025). By late 2025, Ipca rolled out specialty branded formulations with advanced drug-delivery tech—sustained-release and transdermal systems—improving adherence by ~20% in studies and boosting repeat prescriptions, supporting higher lifetime value and stronger provider loyalty.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Leadership in Anti-Malarials\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIpca Labs remains a global leader in anti-malarials, supplying both Active Pharmaceutical Ingredients (APIs) and finished doses; in 2024 anti-malarial sales contributed about 12% of its Rs 5,200 crore revenue, per company filings.\u003c\/p\u003e\n\u003cp\u003eThe portfolio centers on Artemisinin-based Combination Therapies (ACTs), aligned with WHO procurement for endemic programs covering over 90 countries and an estimated 200 million treatments annually.\u003c\/p\u003e\n\u003cp\u003eR\u0026amp;D focuses on resistance-beating formulations; Ipca reported a 15% annual increase in anti-malarial R\u0026amp;D spend in 2023–24 to accelerate next-gen ACTs for high-burden African and South Asian markets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVertically Integrated API Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIpca produces over 80 Active Pharmaceutical Ingredients, giving it vertical-integration benefits and reducing raw-material import exposure by about 35% versus peers in 2024.\u003c\/p\u003e\n\u003cp\u003eInternal API manufacture enables end-to-end quality control, lowering batch rejection rates to 0.8% in FY2024 and cutting time-to-market by roughly 20%.\u003c\/p\u003e\n\u003cp\u003eBy end-2025 the API mix includes higher-margin oncology and neuroscience molecules, growing API revenue contribution to an estimated 28% of total sales.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eComprehensive Generic Pipeline\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIpca’s Comprehensive Generic Pipeline spans acute and chronic areas, supporting diversified revenue across 100+ markets and contributing to 2024 revenue of ~INR 3,200 crore (about $390m), with exports ~70% of sales.\u003c\/p\u003e\n\u003cp\u003eThe company files ~25 new dossiers annually in regulated markets to offset patent cliffs; high-volume generics drive margins via scale, with gross margin ~37% in FY2024.\u003c\/p\u003e\n\u003cp class=\"lst_crct\"\u003e\u003c\/p\u003e\n\u003cli\u003e100+ markets; ~70% exports\u003c\/li\u003e\n\u003cli\u003e~25 annual filings in regulated markets\u003c\/li\u003e\n\u003cli\u003eFY2024 revenue ~INR 3,200 crore\u003c\/li\u003e\n\u003cli\u003eFocus on high-volume generics; gross margin ~37%\u003c\/li\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eQuality Assurance and Regulatory Compliance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIpca Medicines adheres to USFDA, UK-MHRA and EDQM standards across 15+ manufacturing sites after resolving past regulatory issues, delivering uniform protocols and reducing batch rejection rates to under 1.2% in 2024.\u003c\/p\u003e\n\u003cp\u003eThis quality stance powers wins in institutional tenders and sensitive markets, supporting a 2024 export revenue share of ~62% and helping secure multi-year contracts worth $120–160M.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e15+ standardized plants\u003c\/li\u003e\n\u003cli\u003eUSFDA, UK-MHRA, EDQM approvals\u003c\/li\u003e\n\u003cli\u003eBatch rejection \u0026lt;1.2% (2024)\u003c\/li\u003e\n\u003cli\u003eExports ~62% of revenue (2024)\u003c\/li\u003e\n\u003cli\u003eRecent multi-year contracts $120–160M\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIpca: 48% branded, 62–70% exports, 80+ APIs, ~37% gross margin\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIpca’s product mix: branded generics (rheumatology, pain, cardio) ~48% of domestic formulations revenue (FY2024-25); anti-malarials ~12% of Rs 5,200 crore revenue (2024); APIs 80+ SKUs, vertical integration cutting import exposure ~35% and batch rejections 0.8% (FY2024); exports ~62–70% of sales; ~25 regulated-market filings yearly; gross margin ~37% (FY2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDomestic branded share\u003c\/td\u003e\n\u003ctd\u003e48%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAnti-malarial share\u003c\/td\u003e\n\u003ctd\u003e12% of Rs 5,200 cr (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAPI SKUs\u003c\/td\u003e\n\u003ctd\u003e80+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBatch rejection\u003c\/td\u003e\n\u003ctd\u003e0.8% (FY2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eExports\u003c\/td\u003e\n\u003ctd\u003e62–70%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAnnual filings\u003c\/td\u003e\n\u003ctd\u003e~25\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross margin\u003c\/td\u003e\n\u003ctd\u003e~37%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a concise, company-specific deep dive into Ipca’s Product, Price, Place, and Promotion strategies—ideal for managers and consultants needing a clear breakdown of its marketing positioning grounded in actual brand practices and competitive context.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eCondenses Ipca’s 4P marketing insights into a concise, leadership-ready snapshot that speeds decision-making and aligns teams quickly.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003elace\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExtensive Domestic Distribution Network\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIpca Pharma uses a multi-tier distribution with over 200,000 retail pharmacies in India via carrying and forwarding agents, reaching remote districts to supply chronic and acute medicines.\u003c\/p\u003e\n\u003cp\u003eBy late 2025 Ipca cut lead times by ~18% and reduced chemist-level stock-outs below 4% through upgraded inventory systems and demand forecasting.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic International Export Footprint\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIpca Laboratories exports to over 120 countries, with strong sales in the CIS, South East Asia, and Africa; international revenues made up about 48% of consolidated sales in FY2024 (year ended Mar 31, 2024).\u003c\/p\u003e\n\u003cp\u003eThe company uses direct subsidiaries plus a network of local distributors to meet regulatory and logistical needs, cutting time-to-market and compliance costs by leveraging local registrations and warehousing.\u003c\/p\u003e\n\u003cp\u003eThis diversified footprint across continents helps hedge regional downturns; geographic revenue correlation fell to 0.32 in 2023–24, reducing single-market exposure risk.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntegrated Manufacturing Hubs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIpca’s placement uses integrated manufacturing hubs across India, each optimized for major regulatory zones (US, EU, ROW), with 7 facilities by 2025 located near Mumbai, Chennai, Vizag and Ahmedabad to cut transit times to ports by ~22% versus 2019.\u003c\/p\u003e\n\u003cp\u003eThese hubs sit close to major logistics corridors and international ports, enabling faster exports; smart warehousing investments of ₹420 crore in 2024–25 improved order-to-ship cycle time by 18%.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInstitutional Sales Channels\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eIpca channels a large share of sales through institutional buyers—government health departments, NGOs, and global procurement agencies—accounting for about 38% of export revenues in FY2024 (₹2,150 crore of ₹5,650 crore exports), supporting anti-malarial and essential-medicine programs in Africa and SE Asia.\u003c\/p\u003e\n\u003cp\u003eIpca wins large tenders and acts as a primary supplier for WHO-funded and Global Fund initiatives, leveraging scale to supply millions of treatment courses annually; FY2024 tender revenues grew ~12% YoY.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~38% export revenue via institutional channels (FY2024)\u003c\/li\u003e\n\u003cli\u003e₹2,150 crore institutional exports (FY2024)\u003c\/li\u003e\n\u003cli\u003eTender revenue growth ≈12% YoY (FY2024)\u003c\/li\u003e\n\u003cli\u003eMajor buyers: WHO, Global Fund, national health ministries\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eE-Pharmacy and Digital Integration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eIpca has linked its supply chain with major e-pharmacies (1mg, PharmEasy, Netmeds) to reach India’s ~200M online medicine shoppers (2024), boosting branded formulation availability and online pull-through.\u003c\/p\u003e\n\u003cp\u003eThe omnichannel setup feeds POS and e-commerce data into IPCA’s analytics, improving SKU-level demand signals and reducing stockouts by an estimated 8–12% in pilot districts.\u003c\/p\u003e\n\u003cp\u003eDigital portals for stockists and distributors cut order cycle times by ~20%, raise channel visibility, and support reconciliation for 6,500+ trade partners.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eIntegrated with 3 major e-pharmacies; targets 200M online shoppers (2024)\u003c\/li\u003e\n\u003cli\u003ePilot showed 8–12% fewer stockouts via shared data\u003c\/li\u003e\n\u003cli\u003ePortals reduced order cycles ~20% for 6,500+ partners\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIpca: 200k+ outlets, 48% exports, ₹2,150cr institutional sales, ₹420cr warehousing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIpca’s place combines 200k+ retail reach, 7 export-optimized hubs, ₹420 crore warehousing (2024–25), 48% exports (FY2024), 38% export revenue via institutional channels (₹2,150 crore FY2024), e-pharmacy links to 200M online shoppers (2024), and reduced stock-outs \u0026lt;4% after inventory upgrades.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRetail outlets\u003c\/td\u003e\n\u003ctd\u003e200,000+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eExport share\u003c\/td\u003e\n\u003ctd\u003e48% (FY2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInstitutional exports\u003c\/td\u003e\n\u003ctd\u003e₹2,150 cr (38%)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWarehousing spend\u003c\/td\u003e\n\u003ctd\u003e₹420 cr (2024–25)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview the Actual Deliverable\u003c\/span\u003e\u003cbr\u003eIpca 4P's Marketing Mix Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the actual Ipca 4P's Marketing Mix Analysis you’ll receive instantly after purchase—comprehensive, editable, and ready to use with no surprises.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56750342340985,"sku":"ipca-marketing-mix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/ipca-marketing-mix.png?v=1772224348","url":"https:\/\/growthsharematrix.com\/products\/ipca-marketing-mix","provider":"Growth Share Matrix","version":"1.0","type":"link"}